Cassandra Mitchell is being recognized by Continental Who’s Who as a Pinnacle Lifetime Member for her…
Category: Trending
Intensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Intensity Therapeutics, Inc. (“Intensity” or the “Company”) (Nasdaq: INTS), a clinical-stage biotechnology company focused on the discovery…
TraceLink and Value Drug Partner on Drug Supply Chain Security Act (DSCSA) 2023 Compliance to Reduce Cost for Pharmacies
TraceLink Inc., the leading digital network platform company enabling end-to-end product orchestration by connecting more than…
EW Group Signs with China’s Largest Healthcare, Sinopharm
European Wellness Biomedical Group (EW Group), announced its partnership with HK VJM Ltd (representing Sinopharm Cloud…
Elevation Oncology Announces Pricing of $50 Million Public Offering
Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective…
Redwood Pharma presents positive results from a clinical study with RP501 against dry eye
Redwood Pharma AB (publ) announces positive results from the company’s clinical study with RP501, a medical technology…
Fitness & Yoga Campus, Camp Los Angeles, Warms Up for Summer Expansion in West L.A.
Camp Los Angeles – a one-of-a-kind, multi-disciplinary fitness and yoga destination in Santa Monica – is bringing back the summer…
The Rising NAFLD/NASH Epidemic Coupled with High Patient Need Offers Opportunities for Pharmaceutical Manufacturers to Capitalize Across Various Disease Stages, According to Spherix Global Insights
The non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH) epidemic is roughly 2.5 times greater than diabetes in…
Global Cellulite Treatment Global Market 2023-2030: Increasing Trend of Anti-Cellulite Massage Presents Opportunities
The “Global Cellulite Treatment Market 2023-2030” report has been added to ResearchAndMarkets.com’s offering. This research report predicts that the global…
BioLineRx to Report First Quarter 2023 Results on May 24, 2023
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a pre-commercial-stage biopharmaceutical company focused on oncology, announced today that it…